Berte J Baker, DO | |
1500 Eureka Road, Wyandotte, MI 48192 | |
(734) 674-6403 | |
(734) 282-6397 |
Full Name | Berte J Baker |
---|---|
Gender | Female |
Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
Location | 1500 Eureka Road, Wyandotte, Michigan |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1558477323 | NPI | - | NPPES |
4207842 | Medicaid | MI |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 007203 (Michigan) | Primary |
Mailing Address | Practice Location Address |
---|---|
Berte J Baker, DO Po Box 77000, Dept 78309, Detroit, MI 48278-0309 Ph: (734) 674-6403 | Berte J Baker, DO 1500 Eureka Road, Wyandotte, MI 48192 Ph: (734) 674-6403 |
News Archive
CSIRO, Australia's national science agency, has welcomed its role in delivering practical resilience measures in relation to bushfires and climate change, as the country faces continued extreme fire weather in the future.
Obese women who have bariatric surgery before getting pregnant are at significantly lower risk for developing dangerous hypertensive disorders during pregnancy than those who don't, according to a study of medical insurance records by Johns Hopkins experts.
Hyperion Therapeutics, Inc. announced today that its investigational compound glycerol phenylbutyrate (HPN-100) has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) as adjunctive therapy for the chronic management of urea cycle disorders. Hyperion recently completed its phase III trial which was conducted under a Special Protocol Assessment (SPA) agreement with the FDA. The Company plans to announce results from that trial later this year.
Quality Health Plans, a Medicare HMO with 10,000 Florida members, has been ordered into liquidation after failing to come up with the cash reserves the state says were needed. Its members will be moved to another - still unnamed - plan by Dec. 1.
Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA (tranexamic acid) tablets for cyclic heavy menstrual bleeding in the October issue of the peer-reviewed journal, Obstetrics & Gynecology. The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB while maintaining safety and tolerability.
› Verified 6 days ago
Dr. Meryem Melek Langenbach, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2333 Biddle Ave, Wyandotte, MI 48192 Phone: 734-246-6946 | |
Dr. Ruey Chen, MD Pathology Medicare: Medicare Enrolled Practice Location: 2333 Biddle St, Wyandotte, MI 48192 Phone: 734-846-6922 |